Antimelanoma differentiation-associated gene 5 antibody: Expanding the clinical spectrum in North American patients with dermatomyositis

Journal of Rheumatology

Volumn 44, Issue 3, 2017, Pages 319-325

  Moghadam Kia, Siamak ^a   Oddis, Chester V ^a   Sato, Shinji ^b   Kuwana, Masataka ^c   Aggarwal, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b TOKAI UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Anti MDA5 autoantibody; Classic dermatomyositis; Clinical features; Clinically amyopathic dermatomyositis

Indexed keywords

AUTOANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; UNCLASSIFIED DRUG; IFIH1 PROTEIN, HUMAN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOMYOSITIS; DYSPHAGIA; FEMALE; FINGER ULCER; HAND EDEMA; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; PROGNOSIS; PUFFY FINGER; RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE; RASH; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SKIN ULCER; SURVIVAL RATE; UNITED STATES; DISEASE EXACERBATION; IMMUNOLOGY; MIDDLE AGED; PHENOTYPE; SYMPTOM ASSESSMENT;

ADULT; AUTOANTIBODIES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-INDUCED HELICASE, IFIH1; MALE; MIDDLE AGED; PHENOTYPE; SYMPTOM ASSESSMENT;

EID: 85016409760     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160682     Document Type: Article

References (23)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
3. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991;24:959-66.
4. Pearson, C. Arthritis and allied conditions: A textbook of rheumatology, 9th ed. Philadelphia: Lea & Febiger; 1979.
5. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626-36.
6. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006;54:597-613.
7. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-6.
8. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1713-9.
9. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: A multicenter cross-sectional study. Arch Dermatol 2011;147:391-8.
10. Nagata K, Tomii K, Nanjo S, Kubota M, Tachikawa R, Nishio M. [Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody]. [Article in Japanese] Nihon Kokyuki Gakkai Zasshi 2011;49:30-6.
11. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: A review of the literature and a meta-analysis. Arthritis Care Res 2013;65:1316-24.
12. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193-200.
13. Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One 2014;9:e98824.
14. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. J Am Acad Dermatol 2011;65:25-34.
15. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013;65:1307-15.
16. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 2016;68:689-94.
17. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9.
18. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014;73:227-32.
19. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008;58:3593-9.
20. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43:49-54.
21. Pilkington C, Murray K, Isenberg D, Farewell V, Davidson J, Feldman B, et al. Development of disease activity and damage indices for myositis: Initial testing of four tools in juvenile dermatomyositis [abstract]. Arthritis Rheum 2001;44:S294.
22. Rider L, Schiffenbauer A, Villalba M, Adams E, Joe G, Harris-Love M, et al. Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures [abstract]. Arthritis Rheum 2002;46:S612.
23. Sultan SM, Allen E, Cooper R, Kiely P, Oddis C, Lundberg I, et al. Inter-rater reliability of two disease activity and damage tools in patients with idiopathic inflammatory myopathy-report of 105 patients [abstract]. Arthritis Rheum 2004;40:S668.